elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Institutions
beta
Research Intelligence
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
lutetium-177 therapy
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Application
keyword
lutetium-177 therapy
RIS
0.000
(Research Intensity Score)
Papers
10
Top papers
Clinical Best Practices for Radiation Safety During Lutetium-177 Therapy
2022 · 24 citations
Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study
2022 · 14 citations
Uneven Global Distribution of Theranostics
2026 · 1 citations
Illuminating radionuclide therapy response: Monitoring cancer cell and CAF survival in a direct 2D co-culture model
2025 · 2 citations
CDK4/6 inhibition exploits the radiobiology of lutetium-177 therapy to induce replication stress and durable senescence
2026
Newest papers
Uneven Global Distribution of Theranostics
2026 · 1 citations
CDK4/6 inhibition exploits the radiobiology of lutetium-177 therapy to induce replication stress and durable senescence
2026
Evaluating the impact of Lutetium-177 therapy on bioprosthetic heart valves in carcinoid heart disease
2026
O-15 MULTIMODAL TREATMENT APPROACH IN MALIGNANT PHEOCHROMOCYTOMA: AN 8-YEAR FOLLOW-UP CASE
2026
Illuminating radionuclide therapy response: Monitoring cancer cell and CAF survival in a direct 2D co-culture model
2025 · 2 citations
A sample from the 10 top papers behind lutetium-177 therapy.
Create a free account to browse them all →
lutetium-177 therapy's history
Research intensity over time
Explore lutetium-177 therapy's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
lutetium-177 therapy's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link